![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: COL1A2 |
Gene summary for COL1A2 |
![]() |
Gene information | Species | Human | Gene symbol | COL1A2 | Gene ID | 1278 |
Gene name | collagen type I alpha 2 chain | |
Gene Alias | EDSARTH2 | |
Cytomap | 7q21.3 | |
Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | A0A0S2Z3H5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1278 | COL1A2 | C46 | Human | Oral cavity | OSCC | 2.94e-10 | -5.03e-01 | 0.1673 |
1278 | COL1A2 | C51 | Human | Oral cavity | OSCC | 1.03e-32 | 2.89e+00 | 0.2674 |
1278 | COL1A2 | C57 | Human | Oral cavity | OSCC | 1.49e-04 | -3.24e-01 | 0.1679 |
1278 | COL1A2 | C06 | Human | Oral cavity | OSCC | 7.13e-07 | 3.50e+00 | 0.2699 |
1278 | COL1A2 | C07 | Human | Oral cavity | OSCC | 2.08e-05 | 2.97e+00 | 0.2491 |
1278 | COL1A2 | C08 | Human | Oral cavity | OSCC | 3.49e-06 | -4.80e-01 | 0.1919 |
1278 | COL1A2 | C09 | Human | Oral cavity | OSCC | 1.00e-05 | -1.05e-01 | 0.1431 |
1278 | COL1A2 | LN46 | Human | Oral cavity | OSCC | 2.94e-06 | -5.32e-01 | 0.1666 |
1278 | COL1A2 | LP15 | Human | Oral cavity | LP | 6.89e-09 | 3.20e+00 | 0.2174 |
1278 | COL1A2 | LP17 | Human | Oral cavity | LP | 2.85e-04 | 1.05e+00 | 0.2349 |
1278 | COL1A2 | NEOLP-1 | Human | Oral cavity | NEOLP | 1.37e-08 | 4.50e-01 | -0.0194 |
1278 | COL1A2 | NEOLP-2 | Human | Oral cavity | NEOLP | 2.11e-05 | 2.09e-01 | -0.0196 |
1278 | COL1A2 | NEOLP-3 | Human | Oral cavity | NEOLP | 4.77e-07 | 2.89e-01 | -0.0191 |
1278 | COL1A2 | SYSMH1 | Human | Oral cavity | OSCC | 1.48e-05 | -3.93e-01 | 0.1127 |
1278 | COL1A2 | SYSMH2 | Human | Oral cavity | OSCC | 1.54e-08 | -3.92e-01 | 0.2326 |
1278 | COL1A2 | SYSMH3 | Human | Oral cavity | OSCC | 3.64e-08 | -5.17e-01 | 0.2442 |
1278 | COL1A2 | SYSMH4 | Human | Oral cavity | OSCC | 6.08e-10 | -5.29e-01 | 0.1226 |
1278 | COL1A2 | SYSMH5 | Human | Oral cavity | OSCC | 3.75e-02 | -8.58e-02 | 0.0647 |
1278 | COL1A2 | HTA12-9-2 | Human | Pancreas | PDAC | 1.27e-08 | 6.34e-01 | 0.0835 |
1278 | COL1A2 | HTA12-9-3 | Human | Pancreas | PDAC | 3.04e-11 | 1.23e+00 | 0.2045 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:00435893 | Cervix | CC | skin morphogenesis | 8/2311 | 11/18723 | 6.22e-06 | 1.51e-04 | 8 |
GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
GO:00011016 | Cervix | CC | response to acid chemical | 31/2311 | 135/18723 | 4.16e-04 | 4.22e-03 | 31 |
GO:00715595 | Cervix | CC | response to transforming growth factor beta | 50/2311 | 256/18723 | 6.31e-04 | 5.91e-03 | 50 |
GO:00715605 | Cervix | CC | cellular response to transforming growth factor beta stimulus | 49/2311 | 250/18723 | 6.55e-04 | 6.05e-03 | 49 |
GO:00712292 | Cervix | CC | cellular response to acid chemical | 20/2311 | 80/18723 | 1.40e-03 | 1.10e-02 | 20 |
GO:00015037 | Cervix | CC | ossification | 71/2311 | 408/18723 | 1.67e-03 | 1.28e-02 | 71 |
GO:00712301 | Cervix | CC | cellular response to amino acid stimulus | 18/2311 | 71/18723 | 2.01e-03 | 1.47e-02 | 18 |
GO:0070206 | Cervix | CC | protein trimerization | 7/2311 | 17/18723 | 2.72e-03 | 1.85e-02 | 7 |
GO:00432004 | Cervix | CC | response to amino acid | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
GO:00071795 | Cervix | CC | transforming growth factor beta receptor signaling pathway | 38/2311 | 198/18723 | 3.62e-03 | 2.31e-02 | 38 |
GO:0030198 | Cervix | CC | extracellular matrix organization | 52/2311 | 301/18723 | 7.43e-03 | 3.98e-02 | 52 |
GO:0043062 | Cervix | CC | extracellular structure organization | 52/2311 | 302/18723 | 7.92e-03 | 4.17e-02 | 52 |
GO:0031214 | Cervix | CC | biomineral tissue development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
GO:0045229 | Cervix | CC | external encapsulating structure organization | 52/2311 | 304/18723 | 9.00e-03 | 4.57e-02 | 52 |
GO:0030282 | Cervix | CC | bone mineralization | 24/2311 | 119/18723 | 1.00e-02 | 4.89e-02 | 24 |
GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa051465 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa049336 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa046115 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa05415110 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0514612 | Cervix | CC | Amoebiasis | 29/1267 | 102/8465 | 3.31e-04 | 1.70e-03 | 1.01e-03 | 29 |
hsa0493313 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa0461113 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa0541524 | Cervix | HSIL_HPV | Diabetic cardiomyopathy | 30/459 | 203/8465 | 4.38e-07 | 1.07e-05 | 8.64e-06 | 30 |
hsa0451023 | Cervix | HSIL_HPV | Focal adhesion | 21/459 | 203/8465 | 3.24e-03 | 2.02e-02 | 1.63e-02 | 21 |
hsa0541534 | Cervix | HSIL_HPV | Diabetic cardiomyopathy | 30/459 | 203/8465 | 4.38e-07 | 1.07e-05 | 8.64e-06 | 30 |
hsa0451033 | Cervix | HSIL_HPV | Focal adhesion | 21/459 | 203/8465 | 3.24e-03 | 2.02e-02 | 1.63e-02 | 21 |
hsa0541525 | Endometrium | AEH | Diabetic cardiomyopathy | 86/1197 | 203/8465 | 2.62e-23 | 1.22e-21 | 8.90e-22 | 86 |
hsa0451015 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA2_ITGB1 | COL1A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | CD44 | COL1A2_CD44 | COLLAGEN | Breast | ADJ |
COL1A2 | SDC4 | COL1A2_SDC4 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | DCIS |
COL1A2 | ITGA2_ITGB1 | COL1A2_ITGA2_ITGB1 | COLLAGEN | Breast | DCIS |
COL1A2 | CD44 | COL1A2_CD44 | COLLAGEN | Breast | DCIS |
COL1A2 | SDC1 | COL1A2_SDC1 | COLLAGEN | Breast | DCIS |
COL1A2 | SDC4 | COL1A2_SDC4 | COLLAGEN | Breast | DCIS |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | Healthy |
COL1A2 | ITGA2_ITGB1 | COL1A2_ITGA2_ITGB1 | COLLAGEN | Breast | Healthy |
COL1A2 | ITGAV_ITGB8 | COL1A2_ITGAV_ITGB8 | COLLAGEN | Breast | Healthy |
COL1A2 | CD44 | COL1A2_CD44 | COLLAGEN | Breast | Healthy |
COL1A2 | SDC1 | COL1A2_SDC1 | COLLAGEN | Breast | Healthy |
COL1A2 | SDC4 | COL1A2_SDC4 | COLLAGEN | Breast | Healthy |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | IDC |
COL1A2 | CD44 | COL1A2_CD44 | COLLAGEN | Breast | IDC |
COL1A2 | SDC1 | COL1A2_SDC1 | COLLAGEN | Breast | IDC |
COL1A2 | SDC4 | COL1A2_SDC4 | COLLAGEN | Breast | IDC |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | Precancer |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
COL1A2 | SNV | Missense_Mutation | rs140434765 | c.1562N>T | p.Ala521Val | p.A521V | P08123 | protein_coding | tolerated(0.26) | benign(0.433) | TCGA-A2-A04X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
COL1A2 | SNV | Missense_Mutation | novel | c.1811N>A | p.Gly604Asp | p.G604D | P08123 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COL1A2 | SNV | Missense_Mutation | rs72658193 | c.2503N>A | p.Gly835Ser | p.G835S | P08123 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A099-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
COL1A2 | SNV | Missense_Mutation | c.1988N>C | p.Arg663Thr | p.R663T | P08123 | protein_coding | deleterious(0.01) | benign(0.138) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
COL1A2 | SNV | Missense_Mutation | rs749509413 | c.1213C>T | p.Arg405Cys | p.R405C | P08123 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COL1A2 | SNV | Missense_Mutation | c.1565N>T | p.Pro522Leu | p.P522L | P08123 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
COL1A2 | SNV | Missense_Mutation | rs543815305 | c.1419N>G | p.Ile473Met | p.I473M | P08123 | protein_coding | deleterious(0.03) | possibly_damaging(0.454) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
COL1A2 | SNV | Missense_Mutation | c.2587N>T | p.Pro863Ser | p.P863S | P08123 | protein_coding | tolerated(0.05) | benign(0.013) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
COL1A2 | SNV | Missense_Mutation | novel | c.1126G>T | p.Gly376Cys | p.G376C | P08123 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A1HI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
COL1A2 | SNV | Missense_Mutation | c.1186N>A | p.Pro396Thr | p.P396T | P08123 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1278 | COL1A2 | DRUGGABLE GENOME | Solubilized type 1 native bovine collagen | |||
1278 | COL1A2 | DRUGGABLE GENOME | TNF-ALPHA | 12393755 | ||
1278 | COL1A2 | DRUGGABLE GENOME | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | |||
1278 | COL1A2 | DRUGGABLE GENOME | CHEMBL2095222 | OCRIPLASMIN | ||
1278 | COL1A2 | DRUGGABLE GENOME | IFN | 14512876 | ||
1278 | COL1A2 | DRUGGABLE GENOME | CHEMBL2108709 | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ||
1278 | COL1A2 | DRUGGABLE GENOME | COLLAGENASE | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | ||
1278 | COL1A2 | DRUGGABLE GENOME | TGF-BETA 2 | 15223827 | ||
1278 | COL1A2 | DRUGGABLE GENOME | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | |||
1278 | COL1A2 | DRUGGABLE GENOME | TRANSFORMING GROWTH FACTOR | 14520013 |
Page: 1 |